Though the benefit of BRCA1/2 tumor testing is increasingly evident for the purposes of therapeutic decision‐making, the importance of identifying non‐BRCA1/2‐associated hereditary cancer families cannot be overlooked. This evidence concerns the gene BRCA1 and hereditary cancer.